inSeption Group buyer-window signal capture

Evidence

• Intensity's 10-Q for the quarter ended June 30, 2026, filed August 11, 2026, states that in May 2026 the company issued a termination notice to the CRO on its Phase 3 sarcoma study and initiated transition efforts, with a $1.2 million advance still held by that CRO.
• The August 11, 2026 results release says Intensity initiated activities to resume enrollment in a limited number of U.S. sites in the Phase 3 INVINCIBLE-3 study by the third quarter of 2026 under an FDA-reviewed amended protocol, and reports $9.5 million of cash at June 30, 2026.
• The same release reports cash and cash equivalents of $9.5 million as of June 30, 2026, and the 10-Q records substantial doubt about the company's ability to continue as a going concern.

Practical opening

“Its August 2026 10-Q says it served its Phase 3 CRO a termination notice in May 2026. U.S. enrollment in that Phase 3 restarts by the third quarter of 2026 under an amended protocol. So whoever runs that restart is being chosen this quarter, if it has not been already. We could offer the VP of Clinical Operations a fixed-cost restart team.”

Claim boundaryDo not say Intensity has not yet chosen a replacement CRO, that Premier Research was the terminated CRO, or that it has budget for a full-service takeover.

Sixteen people and $9.5 million of cash with a going-concern warning; the budget is thin and a replacement CRO may already be signed.

Evidence

• Context's 10-Q for Q2 2026, filed August 5, 2026, records that on April 2, 2026 the FDA granted Fast Track to CTIM-76 for platinum-resistant ovarian cancer, that the first CT-202 Phase 1 patient is expected in Q3 2026, and that $43.0 million of cash funds operations into Q4 2027.
• The live Associate Director, Clinical Operations posting reports directly to the VP of Clinical Operations and makes high-touch oversight of CROs and other third-party vendors, to ensure study milestones are achieved, the primary focus of the role.
• ClinicalTrials.gov record NCT06515613 for the CTIM-76 Phase 1 study was updated on September 3, 2026 and shows the study recruiting at 15 sites toward an estimated 156 patients.

Practical opening

“The FDA granted Fast Track to its lead program CTIM-76 on April 2, 2026. Its live clinical-operations posting makes oversight of CROs and vendors the primary focus of the role. That suggests the team that manages its CROs is being rebuilt while the lead program accelerates. We could offer the CMO named clinical-operations people beside the existing CROs.”

Claim boundaryDo not say the VP of Clinical Operations has left, that Context is re-bidding its CROs, or that the posting date is known.

Phase 1 CROs are already engaged, so the opening is a function swap or added oversight, not a full-service award; the VP of Clinical Operations seat status is unconfirmed.

Evidence

• The prospectus earmarks IPO proceeds for the planned initiation of a potential registrational Phase 2 trial of BH-30643 in EGFR-mutant lung cancer and says the company expects to dose the first patient in the first quarter of 2027, with an IND for a second program planned the same quarter.
• ClinicalTrials.gov record NCT06706076 shows the Phase 1/2 SOLARA study of BH-30643 recruiting toward an estimated 675 patients, last updated August 5, 2026.
• BlossomHill's live ADP careers board on September 8, 2026 lists a Director of Regulatory Affairs (posted Sept 3), an Associate Director of Medical Writing (Sept 2), a Senior Manager of Drug Safety (Aug 17) and a Clinical Trial Sample Manager (July 13), all San Diego, and no CTM posting.

Practical opening

“Its IPO prospectus commits proceeds to a pivotal Phase 2 with first patient dosing in the first quarter of 2027. Its Phase 1/2 SOLARA study is recruiting toward 675 patients. That suggests the operating plan for the pivotal study is being set now, before the first patient is dosed. We could offer the clinical-operations head named oncology people beside the pivotal study's CRO.”

Claim boundaryDo not say BlossomHill is choosing a CRO for the pivotal, that it has no CRO, or that its SVP of Clinical Operations is open to a new vendor.

SOLARA already runs across dozens of sites in ten countries, so a global CRO is incumbent and the pivotal will likely stay with it; the opening is FSP or rescue beside that CRO, and San Diego is outside the seller's home corridor.